Dec 08, 2020 / 10:00PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to today's top line data from HOPE-B pivotal trial of EtranaDez in hemophilia B. (Operator Instructions) I would also -- I also need to advise you that this conference is recorded today.
Without any further delay, I would now like to hand the conference over to Maria Cantor. Please go ahead.
Maria E. Cantor - uniQure N.V. - Chief Communications Officer
Good afternoon, and thank you for joining us as we review the initial clinical data from the HOPE-B pivotal study of EtranaDez AMT-061 being studied in adult patients with severe and moderately severe hemophilia B. These data were highlighted today in a late-breaker oral presentation featured at the virtual ASH Annual Meeting.
Joining me for this event are Matt Kapusta, our Chief Executive Officer at uniQure; Dr. Ricardo Dolmetsch, our President of Research and Development; Eileen Sawyer, our Vice President of Global Medical Affairs; and Dr. Steven Pipe, Professor of Pediatrics and Pathology and the Pediatric Medical Director of the
uniQure N.V. - Special Call Transcript
Dec 09, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers